Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 10777 - 10784 of 11621 results
Obama Administration Outlines Religious Accommodations for Contraception Coverage Mandate
February 7, 2013| Blog| Viewpoint
CMS Publishes Proposed Changes to CLIA’s Proficiency Testing Regulations
February 5, 2013| Blog| Viewpoint
ML Strategies Publishes Weekly Health Care Reform Update on February 4, 2013
February 5, 2013| Blog| Viewpoint
CMS Publishes Final Sunshine Act Rule; Data Collection to Begin on August 1, 2013
February 4, 2013| Alert| Viewpoint
New Children’s Product Testing and Certification Rule Set to Impact Manufacturers and Importers on February 8
February 4, 2013| Alert| Viewpoint
Let the Collection and Reporting Begin: CMS Publishes Final Sunshine Act Regulations
February 4, 2013| Blog| Viewpoint
Mintz Publishes Comparison of Proposed and Final Sunshine Act Regulations
February 4, 2013| Blog| Viewpoint
DOL, IRS, and HHS Put the Brakes on Stand-Alone HRAs Used to Access Health Insurance Coverage in the Individual Market
February 1, 2013| Advisory| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.